Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.

Journal of the American College of Cardiology - 17 Sept 2024

van den Broek Wout W A, Ingraham Brenden S, Pereira Naveen L, Lee Craig R, Cavallari Larisa H, Swen Jesse J, Angiolillo Dominick J, Ten Berg Jurriën M

Abstract excerpt

The clinical efficacy and safety of antiplatelet agents vary among patients. Consequently, some patients are at increased risk of recurrent ischemic events during treatment. This interindividual variability can be a result of genetic variants in enzymes that play a role in drug metabolism. The field of pharmacogenomics explores the influence of these genetic variants on an individual's drug response. Tailoring...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiplatelet Therapy and Cardiovascular Diseases
Share to Cytochrome P-450 CYP2C19

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Lipoproteins and Cardiovascular Health

Share to Pharmacogenetics

Share to Platelet Aggregation Inhibitors

Share to Prasugrel Hydrochloride

Share to Venous Thromboembolism Diagnosis and Management

Source

Open in PubMed Open full text

Identifiers

PMID: 39260933
DOI: 10.1016/j.jacc.2024.06.038
PMCID: PMC11495226

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genotype-Guided Antiplatelet Therapy: JACC Review Topic of the Week.PMID 39260933Read ↗

Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions.Semantic proximity Read ↗

Pharmacogenetics of Antiplatelet Therapy.Semantic proximity Read ↗

[Genotype-guided antithrombotic therapy].Semantic proximity Read ↗

Give genotype-guided dual antiplatelet therapy a second CHANCE.Semantic proximity Read ↗

Genotype-Guided Antiplatelet Therapy After Coronary Intervention in Patients With High Bleeding Risk - Never Judge a Book by Its Cover.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update.Semantic proximity Read ↗

CYP2C19 genotype-guided antiplatelet therapy: promises and pitfalls.Semantic proximity Read ↗

Genotyping genetic variants of CYP2C19 for precision antiplatelet dosing: state of the art and future perspectives.Semantic proximity Read ↗

Role of Cyp2c19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention.Semantic proximity Read ↗

CYP2C19 Genotype-Guided Antiplatelet Therapy and Clinical Outcomes in Patients Undergoing a Neurointerventional Procedure.Semantic proximity Read ↗

The pharmacogenetics of antiplatelet agents: towards personalized therapy?Semantic proximity Read ↗

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.